{"drugs":["Nasop","Phenylephrine Tannate"],"mono":{"0":{"id":"928169-s-0","title":"Generic Names","mono":"Phenylephrine Tannate"},"1":{"id":"928169-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928169-s-1-4","title":"Adult Dosing","mono":"<b>Nasal congestion:<\/b> 7.5 mg to 15 mg (5 to 10 mL) ORALLY every 12 hours "},"1":{"id":"928169-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Nasal congestion:<\/b> (12 yrs and older) 7.5 mg to 15 mg ORALLY every 12 hours<\/li><li><b>Nasal congestion:<\/b> (6 to 12 yrs) 3.75 mg to 7.5 mg ORALLY every 12 hours<\/li><li><b>Nasal congestion:<\/b> (2 to 6 yrs) 1.875 mg to 3.75 mg ORALLY every 12 hours<\/li><\/ul>"},"3":{"id":"928169-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Nasal congestion<br\/>"}}},"3":{"id":"928169-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928169-s-3-9","title":"Contraindications","mono":"<ul><li>breastfeeding mothers<\/li><li>hypersensitivity to phenylephrine, any related compounds, or any ingredients<\/li><li>newborns<\/li><\/ul>"},{"id":"928169-s-3-10","title":"Precautions","mono":"<ul><li>asthma, bronchial and other lower respiratory disease<\/li><li>bowel obstruction or narrowing<\/li><li>cardiovascular disease<\/li><li>concomitant MAOI or within 14 days of stopping a MAOI<\/li><li>diabetes mellitus<\/li><li>hypertension<\/li><li>hyperthyroidism<\/li><li>increased intraocular pressure<\/li><li>prostatic hypertrophy<\/li><\/ul>"},{"id":"928169-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Phenylephrine: C (FDA)<\/li><li>Phenylephrine: B2 (AUS)<\/li><\/ul>"},{"id":"928169-s-3-12","title":"Breast Feeding","mono":"Phenylephrine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928169-s-4","title":"Drug Interactions","sub":[{"id":"928169-s-4-13","title":"Contraindicated","mono":"<ul><li>Clorgyline (theoretical)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (theoretical)<\/li><li>Linezolid (theoretical)<\/li><li>Nialamide (probable)<\/li><li>Phenelzine (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Rasagiline (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Tranylcypromine (theoretical)<\/li><\/ul>"},{"id":"928169-s-4-14","title":"Major","mono":"<ul><li>Amitriptyline (probable)<\/li><li>Amoxapine (probable)<\/li><li>Clomipramine (probable)<\/li><li>Desipramine (probable)<\/li><li>Dothiepin (probable)<\/li><li>Doxepin (probable)<\/li><li>Furazolidone (theoretical)<\/li><li>Imipramine (probable)<\/li><li>Iobenguane I 123 (theoretical)<\/li><li>Lofepramine (probable)<\/li><li>Midodrine (theoretical)<\/li><li>Nortriptyline (probable)<\/li><li>Opipramol (probable)<\/li><li>Pargyline (probable)<\/li><li>Protriptyline (probable)<\/li><li>Trimipramine (probable)<\/li><\/ul>"},{"id":"928169-s-4-15","title":"Moderate","mono":"<ul><li>Guanethidine (probable)<\/li><li>Propranolol (probable)<\/li><\/ul>"}]},"5":{"id":"928169-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nonulcer dyspepsia<\/li><li><b>Neurologic:<\/b>Feeling nervous, Giddiness, Headache, Insomnia, Restlessness<\/li><\/ul>"},"6":{"id":"928169-s-6","title":"Drug Name Info","sub":{"0":{"id":"928169-s-6-17","title":"US Trade Names","mono":"Nasop<br\/>"},"2":{"id":"928169-s-6-19","title":"Class","mono":"<ul><li>Adrenergic<\/li><li>Alkylarylamine<\/li><li>Decongestant<\/li><li>Sympathomimetic<\/li><\/ul>"},"3":{"id":"928169-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"928169-s-7","title":"Mechanism Of Action","mono":"Phenylephrine hydrochloride, a synthetic sympathomimetic agent, is a powerful post-synaptic alpha-receptor agonist with minimal effect on the beta-receptors of the heart. It exhibits a rapid and moderately extended vasoconstrictor and mydriatic action. Its action in the heart includes elevation of the heart rate and reduction of cardiac output.<br\/>"},"8":{"id":"928169-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928169-s-8-23","title":"Absorption","mono":"Bioavailability: Oral, 38%.<br\/>"},"4":{"id":"928169-s-8-27","title":"Elimination Half Life","mono":"2 to 3 hours.<br\/>"}}},"13":{"id":"928169-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should not take phenylephrine tannate during or within 14 days following MAO inhibitor use.<\/li><li>This drug may cause nonulcer dyspepsia, giddiness, headache, insomnia, nervousness, or restlessness.<\/li><\/ul>"}}}